SCHEMBL2256149

SCHEMBL2256149

O=C(COc1cc(C(F)(F)F)nn1-c1ccccc1Cl)N1CCN(Cc2ccncc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.53
KDM4E B2RXH2 4/20 0.53
MAPT P10636 2/20 0.53
TDP1 Q9NUW8 1/20 0.48
IRAK4 Q9NWZ3 1/20 0.44
HTR7 P34969 1/20 0.43
MDH1 P40925 1/20 0.42
MDH2 P40926 1/20 0.42
GRM5 P41594 2/20 0.41
TSHR P16473 4/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2C19 P33261 1/20 0.41
LMNA P02545 3/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
USP2 O75604 2/20 0.41
GAA P10253 1/20 0.41
TGFBR1 P36897 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2258080 0.92 LMNA (0.48) ALDH1A1KDM4EMAPTHTR7MDH1
SCHEMBL2260004 0.92 ALDH1A1 (0.49) ALDH1A1KDM4EMAPTTDP1HTR7
SCHEMBL2258118 0.89 TP53 (0.49) ALDH1A1KDM4EMAPTGRM5TSHR
SCHEMBL2258849 0.88 LMNA (0.56) ALDH1A1KDM4EMAPTTDP1TSHR
SCHEMBL2257784 0.84 SIGMAR1 (0.48) HTR7GRM5MEN1KMT2ATP53
SCHEMBL2259313 0.84 TP53 (0.61) GRM5LMNATGFBR1TP53
SCHEMBL2258205 0.83 HTT (0.50) ALDH1A1KDM4EMAPTTSHRLMNA
SCHEMBL2256762 0.83 KDM4E (0.57) ALDH1A1KDM4EMAPTIRAK4TSHR
SCHEMBL2257410 0.83 MEN1 (0.48) ALDH1A1KDM4EMAPTGRM5TSHR
SCHEMBL2259046 0.83 MAPT (0.47) ALDH1A1KDM4EMAPTGRM5TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121621-B1 LXR AND FXR MODULATORS EXELIXIS PATENT CO LLC (US) 2014-05-07 EP disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-7998995-B2 LXR and FXR modulators EXELIXIS PATENT COMPANY LLC (US) 2011-08-16 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed
US-20100069367-A1 LXR and FXR Modulators EXELIXIS, INC. (US) 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069367-A1 LXR and FXR Modulators NR1H3, NR1H2, NR1H4 ALDH1A1 3692/4885KDM4E 2153/4885MAPT 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.